Celularity Inc: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 16, 2020 and accepted by EDGAR at Nov 16, 2020, 10:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$208.3k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$658.2k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-07-01 to 2020-09-30 | −$10.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $224.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$37.5k | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $843.6k | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$938.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2020-09-30 | $454.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $520.4k | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $292.4m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $141.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $11.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-09-30 | $5.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-20-037167. Last ingested by Listed: Nov 11, 2026, 02:51 ET. Listed shows no prices and gives no investment advice.